The Marigold Maturation Fund
Marigold Maturation Fund aims to invest in four or more biotech companies within medical biotechnology. Investments in the biotech companies are made as the fund raises capital. MGI Investment Management intends to advance the biotech companies alongside the researchers behind the projects toward a sale within 3-5 years, potentially to big pharma companies.
The fund is expected to have a lifespan of under 10 years. The fund’s capital comes from equity contributions from investors of up to DKK 600,000,000, including costs.
Fund open for investment
Name: Marigold Maturation Fund 1
Business Structure: Limited Partnership
Sector: Medical Biotechnology
Fund is expected to contain 4-8 companies
Closed-end fund to 2034
Hard cap is DKK 600.000.000
No bank financing in the companies
Expected investor rate of return: 20-25%
Dividend Payments from 2028-2030
Minimum investment is DKK 750.000
Interested in expanding your investment portfolio? To explore the opportunities in Biotech?
Request fund material here
About us
Registered AIFM
MGI Investment Management ApS is registered in the Danish Financial Supervisory Authority as an AIFM (Alternative Investment Fund Manager).
FTID: 23312
Auditor
Terms & Conditions
Ernst & Young
Authorised Auditor
CVR 30700228
© Marigold Innovation 2024